GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Board to Consider Q2 & Half-Year Results on November 3, 2026
RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 13 Oct 2026, 04:03 PM IST  ·  BSE ID: c1ac4221-3fcf-4535-aa03-30087ed114ef
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board will meet on November 3, 2026, to approve its financial results for the last three and six months.
🤖 AI Summary
  • GlaxoSmithKline Pharmaceuticals Board meeting scheduled for Tuesday, November 3, 2026.
  • Board will consider and approve un-audited financial results for Q2 FY27.
  • The meeting will also review half-year financial results ended September 30, 2026.
  • Disclosure made pursuant to Regulations 29 & 33 of LODR Regulations, 2015.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this announcement.
👤
Who Is Affected
All shareholders are indirectly affected as the upcoming financial results will provide performance updates for GlaxoSmithKline Pharmaceuticals Ltd.
🔍
Management Signal
The management is adhering to regulatory requirements by scheduling a board meeting for timely financial disclosure.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
GlaxoSmithKline Pharmaceuticals' Q2 & half-year FY27 un-audited financial results post-November 3, 2026.
Any further Board decisions from the November 3, 2026 meeting.
Management commentary on performance during Q2 and half-year FY27.
LOW RISK The filing is a routine board meeting intimation for financial results approval.
💡 Investor Takeaway
GlaxoSmithKline Pharmaceuticals Ltd's Board of Directors will convene on November 3, 2026, to review and approve un-audited financial results for the second quarter and half-year ended September 30, 2026.
📅 Company Track Record
In Q1 FY27, GlaxoSmithKline Pharmaceuticals Ltd reported a Standalone Profit of Rs. 25333 Lakhs, marking a 23.76% YoY increase. For FY26, the company's Consolidated Profit rose to Rs. 103598 Lakhs, and a final dividend of Rs. 57 was declared.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
When is GlaxoSmithKline Pharmaceuticals' next Board meeting?
GlaxoSmithKline Pharmaceuticals' Board of Directors meeting is scheduled for Tuesday, November 3, 2026.
What is the purpose of the GlaxoSmithKline Pharmaceuticals Board meeting on November 3, 2026?
The Board meeting on November 3, 2026, is to consider, approve, and take on record the Un-audited financial results for the second quarter and half year ended September 30, 2026.
Which financial periods will be discussed at the GlaxoSmithKline Pharmaceuticals Board meeting?
The Board will discuss the un-audited financial results for the second quarter and half year ended September 30, 2026.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.